CytoSorbents Achieves Record Total Revenue and CytoSorb Sales in the Second Quarter 2018
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
Go back to CytoSorbents Achieves Record Total Revenue and CytoSorb Sales in the Second Quarter 2018
August 3, 2018 7:36 AM EDT
Maxim Group raised its price target on CytoSorbents (NASDAQ: CTSO) to $18.00 (from $13.00) while maintaining a Buy rating.
Analsyt Jason McCarthy commented:
Cytosorbents reported another quarter of growth with Cytosorb revenues of $5.24M, up sequentially from $4.4Mthe 24th consecutive quarter of y/y...
More
August 3, 2018 6:42 AM EDT
Cowen raised its price target on CytoSorbents (NASDAQ: CTSO) to $15.00 (from $13.00) while maintaining an Outperform rating.
Analyst Josuah Jennings commented, "CTSO again delivered impressive quarterly revenue growth, with product sales of $5.2M, up 72% from last year. Lead product CytoSorb has numerous tailwinds in 2018, including (1) favorable German... More
August 2, 2018 4:51 PM EDT
Cytosorbents (NASDAQ: CTSO) reported Q2 EPS of ($0.19), $0.07 worse than the analyst estimate of ($0.12). Revenue for the quarter came in at $5.8 million versus the consensus estimate of $5.07 million.
Ended Q2 2018 with $25.3 million in cash and cash equivalents.
For earnings history and earnings-related data on Cytosorbents (CTSO) click here.
...
More
